Allied Diagnostics And Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 23-12-2024
- Paid Up Capital ₹ 4.83 M
as on 23-12-2024
- Company Age 31 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
as on 23-12-2024
- Revenue %
(FY 2020)
- Profit 41.12%
(FY 2020)
- Ebitda 91.33%
(FY 2020)
- Net Worth -0.33%
(FY 2020)
- Total Assets -0.90%
(FY 2020)
About Allied Diagnostics And Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 4.83 M.
The company currently has active open charges totaling ₹0.50 M.
Veena Aggarwal and Nilesh Aggarwal serve as directors at the Company.
- CIN/LLPIN
U74899DL1993PTC053210
- Company No.
053210
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Allied Diagnostics And Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Aggarwal  | Director | 01-May-2021 | Current |
Veena Aggarwal  | Director | 21-Nov-2004 | Current |
Financial Performance of Allied Diagnostics And Therapeutics.
Allied Diagnostics And Therapeutics Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 41.12% increase in profit. The company's net worth dipped by a decrease of 0.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Allied Diagnostics And Therapeutics?
In 2019, Allied Diagnostics And Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ijcp Publications Private LimitedActive 34 years 7 monthsVeena Aggarwal and Nilesh Aggarwal are mutual person
- A. N. Emedinexus Technologies Private LimitedActive 9 years 4 months
Veena Aggarwal and Nilesh Aggarwal are mutual person
- Healthy Hospitals Private LimitedActive 27 years 2 months
Veena Aggarwal and Nilesh Aggarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 02 Jun 1998 | ₹0.50 M | Open |
How Many Employees Work at Allied Diagnostics And Therapeutics?
Unlock and access historical data on people associated with Allied Diagnostics And Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Allied Diagnostics And Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Allied Diagnostics And Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
